Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-A02769-38 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.
This study hypothesizes that a 10-day FMV protocol can induce neural adaptations to limit strength loss during unilateral lower limb suspension, offering a novel strategy against neuromuscular function decline.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VIBRATION | Active Comparator | Participants will benefit a local vibration countermeasure program for the knee extensor muscles. |
|
| CONTROLE | Sham Comparator | the control group WILL not receive this countermeasure. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Focal muscle vibration | Device | focal muscle vibration sessions, using small and portable vibrator devices. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Isometric force measurement | Maximal isometric force (% decrease) in knee extension of the immobilized leg will be evaluated | Day 1, 7, 14, 28, 33 |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum voluntary force measurement | Maximum voluntary force (Nm) in knee extension, assessed in isometric (for the immobilized leg and also for the contralateral leg), concentric (+60°/s and +180°/s) and eccentric (-60°/s) conditions. | Day 1, 7, 14, 28, 33 |
| Jumping performance measurement |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| LEONARD FEASSON, PHD | Contact | (0)477120383 | +33 | leonard.feasson@chu-st-etienne.fr |
| Name | Affiliation | Role |
|---|---|---|
| LEONARD FEASSON, PHD | CENTRE HOSPITALIER UNIVERSITAIRE SAINT-ETIENNE | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire | Recruiting | Saint-Etienne | 42055 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D057185 | Sedentary Behavior |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| NO Focal muscle vibration | Device | The control group will not receive any intervention. |
|
Jumping performance (height, in cm), assessed in vertical jump tests (Squat Jump and Counter Movement Jump). |
| Day 1, 7, 14, 28, 33 |
| Postural balance measurement | Postural balance performance (displacement of center of pressure, in mm), assessed in a unipodal postural balance test performed on a strength platform | Day 1, 7, 14, 28, 33 |
| Neuromuscular fatigue measurement | Neuromuscular fatigue (decrease in maximum voluntary force (in %), assessed during a fatigue protocol consisting of quadriceps muscle contractions at incremental force levels. | Day 1, 7, 14, 28, 33 |
| Force-velocity-endurance measurement | Force-velocity-endurance profile, assessed during an effort performed on a cycloergometer at linearly decreasing power values. | Day 1, 7, 14, 28, 33 |
| Voluntary activation level evaluation | Voluntary activation level (in %), determined by the force increment obtained following stimulation during a maximal voluntary isometric contraction. | Day 1, 7, 14, 28, 33 |
| Cortico-spinal excitability measurement | Cortico-spinal excitability, assessed by electromyographic responses (motor evoked potentials, in mV) evoked by transcranial magnetic stimulation (TMS). | Day 1, 7, 14, 28, 33 |
| Spinal excitability evaluation | Spinal excitability (i.e. spinal reflexes, in mV), assessed by recording EMG responses evoked by electrical stimulation of the lumbar vertebrae. | Day 1, 7,14 , 28, 33 |
| Cortical activation of sensorimotor areas measurement | Cortical activation of sensorimotor areas, assessed by recording the electroencephalographic (EEG) signal during submaximal isometric contractions. | Day 1, 7, 14, 28, 33 |
| Muscle volume measurement | Muscle volume will be assessed by ultrasound of the thigh muscles (in cm2). | Day 1, 7, 14, 28, 33 |
| Determination of plasma molecular markers of bone and muscle remodeling | Assessment of blood factors of nerve (BDNF) and muscle remodeling (circulating steroids, insulin, GH, IGF-1, myostatin, activinA, follistatin). | Day 1, 7, 14, 28, 33 |
| Determination of plasma molecular markers of bone and muscle remodeling | Evaluation of bone remodeling factors by bAP, CTx, P1NP and Trap5b assays | Day 1, 7, 14, 28, 33 |
| Plasma molecular markers of thrombotic risk evaluation | Plasma molecular markers of thrombotic risk will be assessed by blood sampling followed by assay of HSP47 and D-dimer factors. | Day 1, 7, 14, 28, 33 |